Accéder au contenu
Merck

Pharmacokinetics and tissue disposition of meloxicam in beef calves after repeated oral administration.

Journal of veterinary pharmacology and therapeutics (2015-02-25)
J F Coetzee, R A Mosher, G R Griffith, R Gehring, D E Anderson, B KuKanich, M Miesner
RÉSUMÉ

The objective of this study was to investigate the pharmacokinetics and tissue disposition of meloxicam after repeated oral administration in calves. Thirteen male British × Continental beef calves aged 4 to 6 months and weighing 297-392 kg received 0.5 mg/kg meloxicam per os once daily for 4 days. Plasma meloxicam concentrations were determined in 8 calves over 6 days after first treatment. Calves were randomly assigned to be euthanized at 5, 10, 15 (n = 3/timepoint), and 19 days (n = 4) after final administration. Meloxicam concentrations were determined in plasma (LOQ= 0.025 μg/mL) and muscle, liver, kidney, and fat samples (LOQ = 2 ng/g) after extraction using validated LC-MS-MS methods. The mean (± SD) Cmax , Cmin , and Caverage plasma meloxicam concentrations were 4.52 ± 0.87 μg/mL, 2.95 ± 0.77 μg/mL, and 3.84 ± 0.81 μg/mL, respectively. Mean (± SD) tissue meloxicam concentrations were highest in liver (226.67 ± 118.16 ng/g) and kidney samples (52.73 ± 39.01 ng/g) at 5 days after final treatment. Meloxicam concentrations were below the LOQ in all tissues at 15 days after treatment. These findings suggest that tissue from meloxicam-treated calves will have low residue concentrations by 21 days after repeated oral administration.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
ββ-Glucuronidase from Helix pomatia, Type H-2, aqueous solution, ≥85,000 units/mL
Sigma-Aldrich
Piroxicam, ≥98% (TLC)